Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

The Heat Shock Protein 32 (Hsp32)/HO-1-Targeting Drug SMA-ZnPP and the Triterpenoid CDDO-Me Exert Synergistic Growth-Inhibitory Effects on TKI-Resistant Leukemic Cells in Ph+ CML

Karoline V. Gleixner, M.D., Harald Herrmann, M.D., Katharina Blatt, M.Sc., Winfried F Pickl, MD, Marina Konopleva, MD, PhD, Gahininath Y Bharate, Michael Andreeff, M.D., Ph.D., Hiroshi Maeda, MD, Peter Valent, M.D.

Blood (2011) 118 (21): 4414.

https://doi.org/10.1182/blood.V118.21.4414.4414

Published: 2011

Journal Articles

Identification of Heat Shock Protein 32 (Hsp32) as a Novel Target in Acute Lymphoblastic Leukemia (ALL).

Renata A. Meyer, MD, Harald Herrmann, MD, Karoline V. Gleixner, MD, Alexander Gruze, Sabine Cerny-Reiterer, MD, Rainer Hubmann, PhD, Medhat Shehata, MD, Matthias Mayerhofer, MD, Wolfgang R. Sperr, MD, Winfried F. Pickl, MD, Junia V. Melo, PhD, Gahininath Y. Bharate, Ulrich Jäger, MD, Hiroshi Maeda, MD, PhD, Peter Valent, MD

Blood (2008) 112 (11): 1616.

https://doi.org/10.1182/blood.V112.11.1616.1616

Published: 2008

Journal Articles

Targeting of Heat Shock Protein 32 (Hsp32) in Neoplastic Cells by Styrene Maleic Acid Zinc Protoporphyrin (SMA-ZnPP) Is Associated with Reduced Growth and Induction of Apoptosis.

Karoline V. Gleixner, MD, Mayerhofer Matthias, MD, Anja Vales, MD, Alexander Gruze, Michael Kneidinger, MD, Gregor Hoermann, Maria T. Krauth, MD, Rudin Kondo, MD, Karoline Sonneck, MD, Puchit Samorapoompichit, MD, Eva Lackner, MD, Khaled Greish, PhD, Winfried F. Pickl, MD, Christian Sillaber, MD, Christoph C. Zielinski, MD, Hiroshi Maeda, MD, Peter Valent, MD

Blood (2006) 108 (11): 4323.

https://doi.org/10.1182/blood.V108.11.4323.4323

Published: 2006

Journal Articles

Heme Oxygenase-1 (HO-1)/Heat Shock Protein 32 (Hsp32) as a Novel Survival Factor and Target in AML.

Michael Kneidinger, MD, Karoline V. Gleixner, md, Rudin Kondo, md, Puchit Samorapoompichit, md, Anja Vales, md, Maria T. Krauth, md, Matthias Mayerhofer, md, Alexander Gruze, Winfried F. Pickl, md, Khaled Greish, Alexandra Boehm, md, Wolfgang R. Sperr, md, Hiroshi Maeda, md, phd, Peter Valent, md

Blood (2006) 108 (11): 1901.

https://doi.org/10.1182/blood.V108.11.1901.1901

Published: 2006

Journal Articles

Heme Oxygenase-1 (HO-1): A Novel KIT D816V-Dependent Target in Neoplastic Human Mast Cells (HMC-1).

Rudin Kondo, MD, Matthias Mayerhofer, MD, Karoline Gleixner, MD, Anja Vales, MD, Maria-Theresa Krauth, MD, Sophia Derdak, MD, Alexander Gruze, Winfried Pickl, MD, Christian Sillaber, MD, Khaled Greish, MD, Hiroshi Maeda, MD, PhD, Peter Valent, MD

Blood (2005) 106 (11): 3521.

https://doi.org/10.1182/blood.V106.11.3521.3521

Published: 2005

Journal Articles

The Heme Oxygenase-1-Targeting Compound PEG-ZnPP Inhibits Growth of Imatinib-Resistant BCR/ABL-Transformed Cells.

Matthias Mayerhofer, MD, Karl J. Aichberger, MD, Stefan Florian, Maria-Theresa Krauth, MD, Sophia Derdak, PhD, Harald Esterbauer, PhD, MD, Oswald Wagner, MD, Winfried F. Pickl, MD, Edgar Selzer, MD, Michael W. Deininger, PhD, MD, Brian J. Druker, MD, Khaled Greish, PhD, Hiroshi Maeda, MD, Christian Sillaber, MD, Peter Valent, MD

Blood (2004) 104 (11): 1986.

https://doi.org/10.1182/blood.V104.11.1986.1986

Published: 2004

NARROW

The Heat Shock Protein 32 (Hsp32)/HO-1-Targeting Drug SMA-ZnPP and the Triterpenoid CDDO-Me Exert Synergistic Growth-Inhibitory Effects on TKI-Resistant Leukemic Cells in Ph+ CML

Identification of Heat Shock Protein 32 (Hsp32) as a Novel Target in Acute Lymphoblastic Leukemia (ALL).

Targeting of Heat Shock Protein 32 (Hsp32) in Neoplastic Cells by Styrene Maleic Acid Zinc Protoporphyrin (SMA-ZnPP) Is Associated with Reduced Growth and Induction of Apoptosis.

Heme Oxygenase-1 (HO-1)/Heat Shock Protein 32 (Hsp32) as a Novel Survival Factor and Target in AML.

Heme Oxygenase-1 (HO-1): A Novel KIT D816V-Dependent Target in Neoplastic Human Mast Cells (HMC-1).

The Heme Oxygenase-1-Targeting Compound PEG-ZnPP Inhibits Growth of Imatinib-Resistant BCR/ABL-Transformed Cells.

Email alerts

ASH Publications

American Society of Hematology

The Heat Shock Protein 32 (Hsp32)/HO-1-Targeting Drug SMA-ZnPP and the Triterpenoid CDDO-Me Exert Synergistic Growth-Inhibitory Effects on TKI-Resistant Leukemic Cells in Ph+ CML

Identification of Heat Shock Protein 32 (Hsp32) as a Novel Target in Acute Lymphoblastic Leukemia (ALL).

Targeting of Heat Shock Protein 32 (Hsp32) in Neoplastic Cells by Styrene Maleic Acid Zinc Protoporphyrin (SMA-ZnPP) Is Associated with Reduced Growth and Induction of Apoptosis.

Heme Oxygenase-1 (HO-1)/Heat Shock Protein 32 (Hsp32) as a Novel Survival Factor and Target in AML.

Heme Oxygenase-1 (HO-1): A Novel KIT D816V-Dependent Target in Neoplastic Human Mast Cells (HMC-1).

The Heme Oxygenase-1-Targeting Compound PEG-ZnPP Inhibits Growth of Imatinib-Resistant BCR/ABL-Transformed Cells.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only